| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.31 | 4e-12 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0002 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.0004 |
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.0004 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | 0.24 | 0.0004 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0006 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.002 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.087 | 0.003 |